Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1991 Jul;29(7):1530–1532. doi: 10.1128/jcm.29.7.1530-1532.1991

Cross-reactive antibodies induced by a monovalent influenza B virus vaccine.

R A Levandowski 1, P A Gross 1, M Weksler 1, E Staton 1, M S Williams 1, J Bonelli 1
PMCID: PMC270149  PMID: 1885750

Abstract

Influenza viruses related to the markedly antigenically divergent strains B/Yamagata/16/88 and B/Victoria/2/87 are circulating in human populations. Adults develop cross-reacting antibodies against recent and earlier influenza B virus strains after vaccination with B/Yamagata/16/88, probably because of previous influenza B virus infections or immunizations. Vaccines containing B/Yamagata/16/88 should adequately protect adults against B/Victoria/2/87 infections.

Full text

PDF
1530

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DAVENPORT F. M., HENNESSY A. V., FRANCIS T., Jr Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med. 1953 Dec;98(6):641–656. doi: 10.1084/jem.98.6.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DAVENPORT F. M., HENNESSY A. V., FRANCIS T., Jr Influence of primary antigenic experience upon the development of a broad immunity to influenza. Trans Assoc Am Physicians. 1957;70:81–90. [PubMed] [Google Scholar]
  3. Frank A. L., Taber L. H., Glezen W. P., Geyer E. A., McIlwain S., Paredes A. Influenza B virus infections in the community and the family. The epidemics of 1976-1977 and 1979-1980 in Houston, Texas. Am J Epidemiol. 1983 Sep;118(3):313–325. doi: 10.1093/oxfordjournals.aje.a113638. [DOI] [PubMed] [Google Scholar]
  4. Harmon M. W., Rota P. A., Walls H. H., Kendal A. P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol. 1988 Feb;26(2):333–337. doi: 10.1128/jcm.26.2.333-337.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kendal A. P., Cate T. R. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol. 1983 Oct;18(4):930–934. doi: 10.1128/jcm.18.4.930-934.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Monto A. S., Maassab H. F. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol. 1981 Jan;13(1):54–57. doi: 10.1128/jcm.13.1.54-57.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Robertson J. S., Bootman J. S., Nicolson C., Major D., Robertson E. W., Wood J. M. The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology. 1990 Nov;179(1):35–40. doi: 10.1016/0042-6822(90)90270-2. [DOI] [PubMed] [Google Scholar]
  8. Rota P. A., Wallis T. R., Harmon M. W., Rota J. S., Kendal A. P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990 Mar;175(1):59–68. doi: 10.1016/0042-6822(90)90186-u. [DOI] [PubMed] [Google Scholar]
  9. Tannock G. A., Paul J. A., Herd R., Barry R. D., Reid A. L., Hensley M. J., Gillett R. S., Gillett S. M., Lawrance P., Henry R. L. Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J Clin Microbiol. 1989 Mar;27(3):524–528. doi: 10.1128/jcm.27.3.524-528.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES